Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsA more affordable option for a rare cancer just got the green light. The FDA approved a generic version of lanreotide injection (referencing Somatuline Depot) for adults with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Made by Amneal Pharmaceuticals, the 120 mg prefilled syringe also received competitive generic therapy designation, signaling its potential to broaden patient access to this important somatostatin analog.
A generic alternative for a rare GI cancer just cleared a major hurdle. The FDA has approved lanreotide injection 120 mg/0.5 mL — a generic referencing the brand-name Somatuline Depot — for adults with unresectable, well- or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Manufactured by Amneal Pharmaceuticals, the single-dose prefilled syringe also received competitive generic therapy (CGT) designation, which is designed to expedite generics for drugs with limited competition. The agent is also approved for acromegaly and carcinoid syndrome.
Lanreotide works as a somatostatin analog, binding to receptors that suppress tumor-promoting hormonal activity. It's administered via deep subcutaneous injection every 4 weeks, with steady-state concentrations typically reached after 4–5 doses.
By the Numbers:
Why it matters: GEP-NETs are rare but increasingly diagnosed tumors. A generic formulation could meaningfully reduce treatment costs and expand access for patients who previously faced barriers to this therapy.